SNX1 mRNA and protein were first demonstrated to be low expressed in colon cancer, and gastric cancer cells with SNX1 deletion showed stronger proliferation ability and were more likely to activate the signal transduction of EGFR-ERK1/2 pathway induced by EGF, along with the sensitivity to anoikis decreased17. This evidence concerns the gene MAPK3 and malignant colon neoplasm.